Hints and tips:
Related Special Reports
...Despite Novo Nordisk and Eli Lilly’s lead, Steensberg believed there was space for others to develop weight-loss products....
...Eli Lilly has made cuts in Europe and reduced the number of clinical trials there, he added. But some campaigners for access to medicines welcomed the proposals....
...Eli Lilly shares closed 6 per cent higher on Tuesday, taking its year-to-date gain to 34 per cent....
...Eli Lilly’s weight-loss drug tirzepatide significantly reduced sleep apnoea problems in a late-stage clinical trial, the pharmaceutical group said on Wednesday, adding to evidence that could encourage more...
...The push into prescriptions and drug delivery is unusual for a pharmaceutical manufacturer, pitting Eli Lilly against pharmacies such as CVS and Walgreens....
...Patients on the donanemab study had more advanced Alzheimer’s than patients on similar studies, Eli Lilly said....
...But that is what Eli Lilly did this week....
...BSP previously produced Covid antibody treatment bamlanivimab for Eli Lilly....
...Eli Lilly was once considered something of an also-ran in the pharmaceutical industry....
...The retail giant struck a deal earlier this month to dispense medication on behalf of Zepbound maker Eli Lilly’s direct-to-consumer service LillyDirect....
...It is also unlikely that Eli Lilly will provide enough doses of the drug to Britain to meet the demand for weight loss treatments....
...Developed respectively by Novo Nordisk and Eli Lilly, they are now being prescribed to millions of people....
...Eli Lilly has called for competition regulators to scrutinise an $11bn deal by its main competitor Novo Nordisk to snap up additional manufacturing capacity, as the rivalry between the drugmakers to dominate...
...Eli Lilly’s share price fell as much as 2.4 per cent in early US trading before later recovering its losses....
...Highlighting continued caution from regulators, the agency last month delayed an approval decision on donanemab, Eli Lilly’s Alzheimer’s drug....
...The side effects of Eli Lilly’s and Novo Nordisk’s obesity treatments are very similar, and patients could switch from one to the other, Stanford said....
...Novo Nordisk is on a 37 times multiple and Eli Lilly on 59 times. Some estimates of the long-term market potential invite parallels with obesity drugs....
...“The obesity field is going to be dominated by those two guys [Novo Nordisk and Eli Lilly] and who wants to go up against them?” he said. “It would be super hard.”...
...They include the popular new diabetes and weight-loss drugs Ozempic and Wegovy, made by Novo Nordisk, and Mounjaro and Zepbound made by Eli Lilly....
...Eli Lilly’s $12.50 a share cash offer for Point represents a 50 per cent premium to the stock’s undisturbed three month average....
...Eli Lilly, the world’s largest drugmaker, plans to bolster its portfolio of cancer drugs by buying Point Biopharma for $1.4bn, paying a premium of almost 90 per cent to Monday’s closing price....
...Isomorphic Labs has partnerships with pharmaceutical companies Eli Lilly and Novartis....
...Both Leqembi and Eli Lilly’s new drug donanemab target amyloid, a toxic protein that builds up in the brain, usually before significant levels of tau develop....
...US drugmaker Eli Lilly is riding a wave of investor optimism and media hype about new treatments for two of the biggest public health problems: obesity and Alzheimer’s....
...Second-quarter results from Eli Lilly showed how quickly demand is increasing....
International Edition